Medical Psilocybin and Psilocin Access
An act to amend the Controlled Drugs and Substances Act and the Food and Drugs Act
Summary
- Reclassifies psilocin and psilocybin for medical use by treating them as "narcotics" under the Narcotic Control Regulations and removing them from the "restricted drugs" category in the Food and Drug Regulations.
- Clarifies definitions in the Controlled Drugs and Substances Act and the Food and Drugs Act so regulated medical access can occur within existing controlled-substances frameworks.
- Automatically grants Health Canada priority review status for new drug submissions involving psilocin, psilocybin, or substantially similar compounds, while maintaining full safety and efficacy approval standards.
- States the aim is to improve access to psychedelic-assisted medical treatment without bypassing core new-drug approval processes.
Builder Assessment
The bill reduces regulatory friction for promising psychedelic therapies and clarifies their medical pathway, likely attracting investment and advancing innovation, with potential productivity gains from improved mental health outcomes. To protect Canadians while unlocking these benefits, implementation should include clear scope, right-sized safeguards, and adequate regulatory capacity.
- Strengths: streamlines access via reclassification and guaranteed priority review; improves investment signals for biotech and clinical research; maintains full approval standards for safety and efficacy.
- Risks: broad “substantially similar” language could invite unintended analogues; automatic priority status may crowd out other urgent reviews if capacity is not expanded; diversion and clinical quality risks if guidance is unclear.
- Suggested improvements: precisely define “substantially similar” in regulation tied to structure-activity and intended pharmacology; publish service standards and a capacity plan for priority reviews; use existing narcotic tracking and digital pharmacovigilance to monitor safety with minimal burden; issue national, evidence-based clinical guidance and streamlined training pathways; encourage domestic GMP manufacturing and clinical-trial infrastructure to capture economic upside.
Question Period Cards
How will the government define what counts as substantially similar compounds so automatic priority review does not sweep in a wide array of analogues and overwhelm the regulator at the expense of other critical therapies?
What concrete safeguards—using existing controlled-substance frameworks—will ensure patient safety, prescriber competence, and diversion prevention as psilocybin transitions to the Narcotic Control Regulations, and when will those be published?
What additional resources and service standards will Health Canada commit so automatic priority reviews for psilocybin-related drugs do not delay approvals for cancer, rare disease, and other life-saving medicines?
Principles Analysis
—
Canada should aim to be the world's most prosperous country.
Potential productivity gains from better mental health treatment are plausible but indirect and uncertain at national scale.
✓
Promote economic freedom, ambition, and breaking from bureaucratic inertia (reduce red tape).
Shifts psilocybin/psilocin out of a more restrictive category and guarantees priority review, streamlining access within existing safeguards.
✓
Drive national productivity and global competitiveness, including removing interprovincial trade barriers and improving labour mobility (one country, one market).
Positions Canada to compete in psychedelic medicine by accelerating clinical development and enabling a clearer medical pathway.
—
Grow exports of Canadian products and resources, and move up the value chain by processing resources domestically rather than exporting them raw.
Could enable future pharmaceutical exports if therapies succeed, but the bill includes no direct export mechanisms.
✓
Encourage investment, innovation, and resource development.
Regulatory clarity and faster review timelines can attract capital and R&D into novel therapies and supporting clinical infrastructure.
—
Deliver better public services at lower cost (government efficiency).
Priority reviews may speed specific files but could strain Health Canada unless resourced; efficiency outcomes are uncertain.
—
Reform taxes to incentivize work, risk-taking, and innovation.
No tax measures are included.
—
Focus on large-scale prosperity, not incrementalism.
A targeted sectoral reform; potential health and biotech benefits, but not a broad prosperity initiative.
Did we get the builder vote wrong?
Email [email protected]
PartyMember of Parliament
StatusOutside the Order of Precedence
Last updatedN/A
TopicsHealthcare, Criminal Justice
Parliament45